key: cord-1033036-o44q1sag
authors: Piedad Ussetti Gil, M.
title: Impact of COVID-19 infection on lung transplantation management
date: 2022-04-15
journal: Arch Bronconeumol
DOI: 10.1016/j.arbres.2022.03.004
sha: 30161b28d32a836a343dc35e921ad7e8812d7faf
doc_id: 1033036
cord_uid: o44q1sag

nan

The activity of lung transplant programmes has been significantly affected since the beginning of the COVID-19 pandemic by a drop in the number of donors and the surgical capacity of hospital centres. During the lockdown period, organ donation was almost paralyzed due to the saturation of intensive care units and the use of operating theatres as care units for critically ill patients. The cyclic evolution of the pandemic and the rapid response from the National Transplant Organization managed to sustain lung transplant activity. Currently, many programs have almost fully recovered the pre-pandemic activity ( Fig. 1) . However, the pandemic is still having an especially negative impact on lung transplant recipients. The airborne transmission of the virus coupled with the characteristics of lung grafts and immunosuppression make lung transplant recipients especially vulnerable to both infection and the development of severe forms of the disease. The mortality associated with pneumonia due to severe acute respiratory SARS-CoV-2 syndrome in these patients can be in excess of 40% 1-3 and is a clear reflection of the ineffectiveness of the prevention and treatment measures applied to now.

Vaccination is necessary, but is not enough to protect these patients. 4 Fewer than half of transplant recipients generate a protective response despite repeated vaccination cycles. 5 The factors associated to this reduced vaccine response are the intensity of immunosuppression, hypogammaglobulinaemia, and the use of anti-metabolitesespecially mycophenolate. It is therefore advisable for lung transplant recipients to maintain the adherence to basic personal protection measures such as FFP2 face masks, hand hygiene, social distancing and the adequate ventilation of closed spaces.

The protection of patients with little or no vaccine response may significantly improve with the availability of long-acting monoclonal antibodies. Evusheld ® is a combination of two long-acting antibodies (tixageviman-cilgavimab) recently approved by the Food and Drug Administration for pre-exposure prophylaxis of patients without vaccine response. 6 The intramuscular availability of the drug facilitates the administration at the outpatient level.

Evusheld ® confers six-month protection against infection from different strains of SARS-CoV-2, including Delta. The level of protection against Omicron is unknown because the clinical trial was performed when this variant was not yet prevalent. The drug should be administered every 6 months in case of pandemic persistence.

For patients in the initial stages of the disease, the only therapeutic tools available have been the temporarily reduction of immunosuppression, the dose adjustments of corticosteroids and/or prophylactic anticoagulation. Progressive forms of the disease have been treated with remdesivir, bolus administration of steroids, immunomodulators and advanced respiratory support with uncertain results. Fortunately, the therapeutic armamentarium to prevent disease progression has been significantly increased in recent months with the incorporation of effective antivirals and monoclonal antibodies. The risk of hospitalisation and death is significantly reduced with the early administration of remdesivir, the nirmatrelvir-ritonavir combination (Paxlovid ® ) or molnupiravir. [7] [8] [9] Monoclonal antibodies are also effective to prevent progression, but the efficacy of many has been reduced with the emergence of the Omicron variant. Sotrovimab is the only antibody that maintains activity against all strains of SARS CoV-2 currently circulating due to its design based on an ancestral epitope of the pan-sarbecovirus family. 10 We have no data from clinical trials on immunosuppressed patients, but favourable clinical The last 2 years of COVID-19 pandemic have taken the lives of too many patients.

Moreover, the weaknesses of our health care system and the chronic shortage of resources have been made evident. There are optimistic predictions foreseeing the end of the pandemic, but the Omicron variant has proven that we are still at risk. Therefore, we must remain alert and prepared to deliver the best available care during the pandemic waves as 

COVID-19 in transplant recipients: The Spanish experience

COVID-19 in lung transplant recipients: A multicenter study

COVID-19 in lung transplant recipients-Risk prediction and outcomes

Real-world effectiveness of the Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against SARS-CoV-2 in solid organ and islet transplant recipients

Impaired humoral response to third dose of BNT162b2 mRNA COVID-19 vaccine despite detectable spike protein-specific T cells in lung transplant recipients

Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19

Early remdesivir to prevent progression to severe COVID-19 in outpatients

Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19

Epub ahead of print

Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients

Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab

A programmatic response, including bamlanivimab or casirivimab-imdevimab administration, reduces hospitalization and death in COVID-19 positive abdominal transplant recipients

Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: Daily home spirometry versus standard pulmonary function testing

Impact of a mobile health intervention on long-term nonadherence after lung transplantation: follow-up after a randomized controlled trial

Outcomes of telehealth care for lung transplant recipients

An e-learning program improves patients' knowledge after lung transplantation